Affordable Access

deepdyve-link
Publisher Website

Efficacy of abiraterone acetate in castration-resistant metastatic prostate cancer: A real-world data analysis.

Authors
  • Oyman, Abdilkerim1
  • Başak, Mustafa2
  • Özçelik, Melike1
  • Özyükseler, Deniz Tataroğlu2
  • Işık, Selver3
  • Yıldırım, Mahmut Emre2
  • 1 Department of Medical Oncology, Unıversity of Health Sciences, İstanbul Ümraniye Training and Research Hospital, Istanbul, Turkey. , (Turkey)
  • 2 Dr. Lutfi Kırdar, Kartal Education and Research Hospital, Istanbul, Turkey. , (Turkey)
  • 3 Erzurum Education and Research Hospital, Erzurum, Turkey. , (Turkey)
Type
Published Article
Journal
Asia-Pacific journal of clinical oncology
Publication Date
Oct 01, 2021
Volume
17
Issue
5
Identifiers
DOI: 10.1111/ajco.13426
PMID: 32892496
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The aim of this study was to evaluate the efficacy of abiraterone in patients with castration-resistant metastatic prostate cancer. We retrospectively analyzed 51 patients with mCRPC treated with abiraterone acetate from January 2014 to August 2018. Clinicopathological information, treatment modalities, treatment responses, and survival times were retrospectively reviewed. A total of 51 patients who received abiraterone 1000 mg/day + prednisone 10 mg/day between January 2014 and August 2018 were included in the study. Of these patients, 33 (64.7%) had post-chemotherapy (CT) and 18 (35.3%) had CT-naive abiraterone receipt. Median overall survival (OS) was 17.3 months (range 9.3-33.1). Median OS was found to be 12.7 months (range 9.4-18.3) and 29.4 months (range 9.3-33.0) in the CT-naive and post-CT group, respectively (P = .236). Median radiographic PFS (rPFS) was 10.1 months (range 4.5-18.4). In the CT-naive group, rPFS was 10.1 months (IQR 6.0-14.7) and in the post-CT group, it was 9.7 months (range 4.0-18.4) (P = .808). PSA progression-free survival (PSA-PFS) was 9.1 months (range 4.6-13.1). In the CT-naive group, PSA-PFS was 7.4 months (range 4.6-13.4) and in post-CT, it was 9.1 months (range 4.8-13.1) (P = .843). These results show that abiraterone acetate is an effective and reliable agent in real-life data. © 2020 John Wiley & Sons Australia, Ltd.

Report this publication

Statistics

Seen <100 times